<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00851409</url>
  </required_header>
  <id_info>
    <org_study_id>C1 1207</org_study_id>
    <nct_id>NCT00851409</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration</brief_title>
  <acronym>OPERA</acronym>
  <official_title>An Open-label Exploratory Phase II Study of the Safety and Immunogenicity of Repeated &quot;rhC1INH&quot; Administration of 50 U/Kg in Patients With Hereditary C1 Inhibitor Deficiency (&quot;HAE&quot;)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharming Technologies B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharming Technologies B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hereditary angioedema (&quot;HAE&quot;) is a disease characterized by recurrent tissue swelling
      affecting various body locations. Recent literature shows that patients with frequent attacks
      may benefit from long-term prophylaxis. This study aims to evaluate the safety and
      prophylactic effect of weekly administrations of 50 IU/kg recombinant C1 Inhibitor
      (&quot;rhC1INH&quot;).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HAE Attacks/Week</measure>
    <time_frame>8 weeks</time_frame>
    <description>Prior to the treatment period, patients enrolled in the study, were asked about the amount of &quot;HAE&quot; attacks in the past 2 years, (calculated to attacks/week), this number is defined as &quot;Historical&quot;. During the treatment period, patients received a dose of 50 IU/kg of &quot;rhC1INH&quot; administered by slow &quot;IV&quot; injection over 4 to 5 minutes, once a week during an eight week period. The amount of attacks during this period is defined as &quot;Prophylaxis&quot; (calculated to attacks/week).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Evaluation of Pharmacokinetic/ Pharmacodynamic (&quot;PK/PD&quot;)Parameters.</measure>
    <time_frame>8 weeks</time_frame>
    <description>&quot;PK/PD&quot; parameters will be based on concentration time curves after the 1st and 8th &quot;rhC1INH&quot; administration.(ratio visit 8/ visit 1, based on the area under the curve from baseline up to 4 hours after administration (AUC 0-4)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Genetic Disorders</condition>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>Recombinant Human C1 Inhibitor</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Weekly administration of 50 IU/kg recombinant human C1 inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human C1 Inhibitor</intervention_name>
    <description>50 IU/kg &quot;rhC1INH&quot;, &quot;IV&quot; injection over 4 to 5 minutes, once weekly over an 8-week treatment period.</description>
    <arm_group_label>Recombinant Human C1 Inhibitor</arm_group_label>
    <other_name>&quot;rhC1INH&quot;</other_name>
    <other_name>Ruconest</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged at least 18 years

          -  Signed informed consent

          -  Comfirmed diagnosis of HAE with baseline plasma level of functional C1INH activity of
             less than 50% of normal, and/or proven HAE ,mutation in C1INH gene.

        Exclusion Criteria:

          -  A history of anaphylaxis or severe allergy (i.e. requiring medication) to food,
             proteins and/or drugs.

          -  A history of allergic reactions to C1INH products or rabbit protein.

          -  Any reported SAE related to study drug administration (withdrawal criterium)

          -  Elevated IgE against rabbit dander (&gt;0.35 kU/L; ImmunoCap assay; Phadia)

          -  A diagnosis of acquired C1INH deficiency.

          -  Woman of child bearing potential, pregnancy or breast-feeding

          -  previous treatment within the last 3 months with plasma-derived C1INH

          -  Any clinically significant abnormality in the routine haematology, biochemistry and
             urinalysis

          -  Any condition or treatment that in the opinion of the investigator might interfere
             with the evaluation of the study objectives.

          -  Any changes since screening that would exclude subject based on above exclusion
             criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Giannetti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>COO Pharming</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For information on sites, please contact Pharming Technologies</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency County Hospital, Internal Medicin Clinica, Allergology-Immunology Department</name>
      <address>
        <city>Tirgu Mures</city>
        <zip>541103</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2009</study_first_submitted>
  <study_first_submitted_qc>February 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2009</study_first_posted>
  <results_first_submitted>November 9, 2012</results_first_submitted>
  <results_first_submitted_qc>December 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 31, 2013</results_first_posted>
  <last_update_submitted>December 20, 2012</last_update_submitted>
  <last_update_submitted_qc>December 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with a history of frequent attacks, defined as &quot;HAE&quot; attacks occurring at least every two weeks were included in the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Recombinant Human C1 Inhibitor</title>
          <description>Weekly administration of 50 IU/kg recombinant human C1 inhibitor
Recombinant Human C1 Inhibitor : 50 IU/kg &quot;rhC1INH&quot;, &quot;IV&quot; injection over 4 to 5 minutes, once weekly over an 8-week treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Recombinant Human C1 Inhibitor</title>
          <description>Weekly administration of 50 IU/kg recombinant human C1 inhibitor
Recombinant Human C1 Inhibitor : 50 IU/kg &quot;rhC1INH&quot;, &quot;IV&quot; injection over 4 to 5 minutes, once weekly over an 8-week treatment period.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HAE Attacks/Week</title>
        <description>Prior to the treatment period, patients enrolled in the study, were asked about the amount of &quot;HAE&quot; attacks in the past 2 years, (calculated to attacks/week), this number is defined as &quot;Historical&quot;. During the treatment period, patients received a dose of 50 IU/kg of &quot;rhC1INH&quot; administered by slow &quot;IV&quot; injection over 4 to 5 minutes, once a week during an eight week period. The amount of attacks during this period is defined as &quot;Prophylaxis&quot; (calculated to attacks/week).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human C1 Inhibitor</title>
            <description>Recombinant Human C1 Inhibitor : 50 IU/kg &quot;rhC1INH&quot;, &quot;IV&quot; injection over 4 to 5 minutes, once weekly over an 8-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>HAE Attacks/Week</title>
          <description>Prior to the treatment period, patients enrolled in the study, were asked about the amount of &quot;HAE&quot; attacks in the past 2 years, (calculated to attacks/week), this number is defined as &quot;Historical&quot;. During the treatment period, patients received a dose of 50 IU/kg of &quot;rhC1INH&quot; administered by slow &quot;IV&quot; injection over 4 to 5 minutes, once a week during an eight week period. The amount of attacks during this period is defined as &quot;Prophylaxis&quot; (calculated to attacks/week).</description>
          <units>attacks/week</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Historical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.51" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylaxis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.27" upper_limit="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Evaluation of Pharmacokinetic/ Pharmacodynamic (&quot;PK/PD&quot;)Parameters.</title>
        <description>&quot;PK/PD&quot; parameters will be based on concentration time curves after the 1st and 8th &quot;rhC1INH&quot; administration.(ratio visit 8/ visit 1, based on the area under the curve from baseline up to 4 hours after administration (AUC 0-4)</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human C1 Inhibitor</title>
            <description>Weekly administration of 50 IU/kg recombinant human C1 inhibitor
Recombinant Human C1 Inhibitor : 50 IU/kg &quot;rhC1INH&quot;, &quot;IV&quot; injection over 4 to 5 minutes, once weekly over an 8-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>The Evaluation of Pharmacokinetic/ Pharmacodynamic (&quot;PK/PD&quot;)Parameters.</title>
          <description>&quot;PK/PD&quot; parameters will be based on concentration time curves after the 1st and 8th &quot;rhC1INH&quot; administration.(ratio visit 8/ visit 1, based on the area under the curve from baseline up to 4 hours after administration (AUC 0-4)</description>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Functional C1 Inhibitor level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" lower_limit="0.98" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antigenic C1 Inhibitor level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.91" upper_limit="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C4 level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.74" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment emergent adverse events (&quot;TEAEs&quot;) were defined as events with start from onset of study drug administration. All Serious Adverse Events(&quot;SAEs&quot;)are listed.</time_frame>
      <desc>All Adverse Events (&quot;AEs&quot;)occurring within 7 days of onset after study drug administration have been listed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Recombinant Human C1 Inhibitor</title>
          <description>Weekly administration of 50 IU/kg recombinant human C1 inhibitor
Recombinant Human C1 Inhibitor : 50 IU/kg &quot;rhC1INH&quot;, &quot;IV&quot; injection over 4 to 5 minutes, once weekly over an 8-week treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Laryngeal edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia-mild</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Anaemia-moderate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator must provide a copy of any results communication to the sponsor for review at least 30 days prior to its submission or disclosure. The sponsor may request to delete information identified by sponsor as confidential information prior to submitting such manuscript and/or abstract for publication. For a multi-center study, the investigator must wait (i) at least 24 months after the study is completed at all sites or (ii) until after the multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs Department</name_or_title>
      <organization>Pharming Technologies BV</organization>
      <phone>+31715247400</phone>
      <email>medicalinfo@pharming.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

